About this item:

48 Views | 33 Downloads

Author Notes:

Kristie A. Blum, Emory University School of Medicine, Atlanta, GA. Email: kristie.blum@emoryhealthcare.org

Kristie A. Blum ORCID: https://orcid.org/0000-0003-4229-2569

Conflict of Interest: None Declared.


Research Funding:

National Cancer Institute, Grant/Award Number: NCT00117975, NCT00553501, NCT01145495 and NCI K24CA201524


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • biologic agents
  • early progression
  • follicular lymphoma
  • immunotherapy
  • PFS24
  • RISK

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Show all authors Show less authors


Journal Title:

Cancer Medicine


Volume 8, Number 1


, Pages 165-173

Type of Work:

Article | Final Publisher PDF


Follicular lymphoma (FL) patients treated with firstline R-CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)-based nonchemotherapy doublet trials: R-galiximab (Anti-CD80, CALGB 50402), R-epratuzumab (Anti-CD22, CALGB 50701), and R-lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24 months from study entry. Twenty-eight percent (48/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 1.50-12.5), P = 0.007). For early POD, the 2-year survival was 80% vs 99% for nonearly POD, and the 5-year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.

Copyright information:

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote